Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Nachury

Showing results (21-30 of 96) with videos related to

Pageof 10
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 20, 2022
Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH StudyAnthony Buisson, Maria Nachury, Maud Reymond, et al.
Journal of Crohn'S & Colitis|May 14, 2024
Real-World Comparison of the Effectiveness between Ustekinumab and Vedolizumab in Patients with Ulcerative Colitis Exposed to at least One Anti-TNF AgentMathurin Fumery, Mélanie Serrero, Guillaume Bouguen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 26, 2019
Efficacy and Safety of Tumor Necrosis Factor Antagonists in Treatment of Internal Fistulizing Crohn's DiseaseGuillaume Bouguen, Audrey Huguet, Aurélien Amiot, et al.
Alimentary Pharmacology & Therapeutics|November 19, 2022
Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agentAnthony Buisson, Maria Nachury, Thomas Guilmoteau, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 20, 2025
Real-world comparison of the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis: the TORUS studyAnthony Buisson, Mélanie Serrero, Romain Altwegg, et al.
European Journal of Gastroenterology & Hepatology|July 28, 2018
Oral vancomycin induces sustained deep remission in adult patients with ulcerative colitis and primary sclerosing cholangitisGuillaume Pineton de Chambrun, Maria Nachury, Natalie Funakoshi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 31, 2019
Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled TrialGilles Bommelaer, David Laharie, Stéphane Nancey, et al.
Digestive Diseases and Sciences|December 8, 2019
Radiological Response Is Associated with Better Outcomes and Should Be Considered a Therapeutic Target in Crohn's DiseaseEléonore Hallé, Mustapha Azahaf, Nicolas Duveau, et al.
BMC Gastroenterology|December 2, 2022
Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective studyCassandra Rayer, Maria Nachury, Arnaud Bourreille, et al.
BMC Gastroenterology|February 2, 2023
Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective studyCassandra Rayer, Maria Nachury, Arnaud Bourreille, et al.
Pageof 10

Showing results (21-30 of 96) with videos related to

Sort By:
Pageof 10
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 20, 2022
Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH StudyAnthony Buisson, Maria Nachury, Maud Reymond, et al.
Journal of Crohn'S & Colitis|May 14, 2024
Real-World Comparison of the Effectiveness between Ustekinumab and Vedolizumab in Patients with Ulcerative Colitis Exposed to at least One Anti-TNF AgentMathurin Fumery, Mélanie Serrero, Guillaume Bouguen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 26, 2019
Efficacy and Safety of Tumor Necrosis Factor Antagonists in Treatment of Internal Fistulizing Crohn's DiseaseGuillaume Bouguen, Audrey Huguet, Aurélien Amiot, et al.
Alimentary Pharmacology & Therapeutics|November 19, 2022
Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agentAnthony Buisson, Maria Nachury, Thomas Guilmoteau, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 20, 2025
Real-world comparison of the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis: the TORUS studyAnthony Buisson, Mélanie Serrero, Romain Altwegg, et al.
European Journal of Gastroenterology & Hepatology|July 28, 2018
Oral vancomycin induces sustained deep remission in adult patients with ulcerative colitis and primary sclerosing cholangitisGuillaume Pineton de Chambrun, Maria Nachury, Natalie Funakoshi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 31, 2019
Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled TrialGilles Bommelaer, David Laharie, Stéphane Nancey, et al.
Digestive Diseases and Sciences|December 8, 2019
Radiological Response Is Associated with Better Outcomes and Should Be Considered a Therapeutic Target in Crohn's DiseaseEléonore Hallé, Mustapha Azahaf, Nicolas Duveau, et al.
BMC Gastroenterology|December 2, 2022
Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective studyCassandra Rayer, Maria Nachury, Arnaud Bourreille, et al.
BMC Gastroenterology|February 2, 2023
Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective studyCassandra Rayer, Maria Nachury, Arnaud Bourreille, et al.
Pageof 10